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Introduction
A continuous infusion of the beta-blocker esmolol has
recently been demonstrated to increase stroke volume
without increasing norepinephrine dosage or impairing
microcirculation in patients with septic shock [1]. In
addition, a pre-existing oral therapy with beta-blockers
was associated with a potential 28-day mortality survival
benefit in septic patients [2]. The influence of a new
initiated or discontinued oral beta-blocker therapy upon
90-day mortality, however, remains unclear.
Objectives
We hypothesized that a new initiated therapy with oral
beta-blocker reduces 90-day mortality in patients with
severe sepsis or septic shock, while discontinuation of a
pre-existing treatment increases it.
Methods
The present observational, single-center cohort study of
intensive care unit (ICU) patients with primary severe
sepsis or septic shock at the University Hospital of
Greifswald, Germany, was performed from January 2010
to December 2013. The local ethics committee approved
the study (Identifier: BB 133/10) and waived a written
informed consent because of the anonymous data collec-
tion and the quality saving and observing character of
the study. The study complied with the Declaration of
Helsinki and was performed according to the responsible
data protection board. The oral administration of beta-
blockers (bisoprolol, carvedilol, metoprolol, nebivolol,
atenolol, talinolol, propranolol, sotalol) before as well as
during ICU stay and 90-day mortality were registered.
Categorical data are expressed as percentages and counts.
Results
580 adult patients were included.
Discontinuation of a pre-existing administration with
beta-blockers during sepsis therapy was associated with
an increased 90-day mortality of 71% (42/59) compared
to 42% (96/226) in patients with a continued therapy
(OR 3.35; 95% CI 1.80 - 6.23) (p < 0.001). The number
needed to harm was 3.48 (95% CI 2.38 - 6.46).
In contrast, a new initiated therapy of oral beta-blockers
reduced 90-day mortality from 42% (77/181) in patients
without beta-blocker therapy before and during sepsis to
28% (32/114) (OR 0.52, 95% CI 0.32 - 0.87) (p < 0.05). The
number needed to treat was 6.9 (95% CI 3.93 - 28.40).
A chronic, pre-existing beta-blocker therapy did not
improve 90-day mortality if continued during sepsis
therapy in comparison to patients who did neither get
beta-blocker treatment before or during sepsis (OR 1.00;
95% CI 0.68 - 1.49) (p > 0.05).
Conclusions
The present results suggest that a pre-existing therapy
with oral beta-blockers should not be stopped in
patients with severe sepsis and septic shock. In addition,
the new initiation of beta-blocker therapy should be
considered in these patients after initial stabilization.
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Randomized, controlled studies are required to confirm
these results.
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